ClinicalTrials.gg
CompletedNCT04113668Updated Aug 5, 2020

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

A Phase 1 interventional study of BMS-986165 and diflunisal in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-05.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Nov 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

  • Women and men must agree to follow instructions for methods of .
  • Participants must be willing and able to complete all study-specific procedures and visits.
  • A healthy participant, as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
  • must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of active liver disease
  • History of biliary disorders, including Gilbert's syndrome or Dubin- Johnson disease, in addition to, current or recent gastrointestinal disease that could impact the absorption of study drug.
  • Participants using electronic cigarettes or nicotine-containing products who have stopped smoking less than 6 months prior to dosing on Day 1.
  • Consumption of chargrilled meat, quinine, or any nutrient known to modulate CYP enzyme activity within 14 days prior to first administration of study treatment.
  • History of any significant drug allergy

Other inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Arm A: Single Dose (BMS-986165)

    Drug: BMS-986165

  • Experimental
    Arm B:Diflunisal and Single Dose (BMS-986165)

    Drug: BMS-986165 · Drug: diflunisal

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986165 with and without UGT1A9 inhibitor

    Time frame: Up to 14 days

  2. Area under the plasma concentration-time AUC (0-T) of BMS-986165 with and without UGT1A9 inhibitor

    Time frame: up to 14 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time AUC(INF) for BMS-986165 with and without UGT1A9 inhibitor

    Time frame: up to 14 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: up to 48 days

  2. Number of participants with 12-lead Electrocardiogram (ECG) Abnormalities

    Time frame: up to 48 days

  3. Physical Examination of weight

    Time frame: up to 48 days

  4. Number of changes in blood pressure

    Time frame: up to 20 days

  5. Number of changes in body temperature

    Time frame: up to 20 days

  6. Number of changes in respiratory rate

    Time frame: up to 20 days

  7. Number of clinical significant changes in lab assessment of blood serum

    Time frame: up to 48 days

  8. Number of Clinically significant changes in assessment of blood

    Time frame: up to 20 days

  9. Number of Clinically significant changes in lab assessment of urine

    Time frame: up to 20 days

07

Study locations

1 site
  • PRA Health Sciences - Lenexa
    Lenexa, Kansas 66219, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2019
First posted
Oct 3, 2019
StartActual
Oct 1, 2019
Primary completionActual
Nov 19, 2019
CompletionActual
Nov 25, 2019
Last update
Aug 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04113668
Responsible party
Sponsor
First posted
Oct 3, 2019
Start date
Oct 1, 2019
Primary completion
Nov 19, 2019
Completion
Nov 25, 2019
Last update
Aug 5, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion